Swedish Orphan Biovitrum AB (publ) (SWOBY)
| Market Cap | 17.59B +49.3% |
| Revenue (ttm) | 3.20B +14.8% |
| Net Income | 663.97M +50,884.6% |
| EPS | 0.96 +50,500.5% |
| Shares Out | n/a |
| PE Ratio | 24.15 |
| Forward PE | 19.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14 |
| Open | 23.10 |
| Previous Close | 23.10 |
| Day's Range | 23.10 - 23.10 |
| 52-Week Range | 16.25 - 29.32 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About SWOBY
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Financial Performance
In 2025, SWOBY's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.
Financial numbers in SEK Financial StatementsNews
Börje Ekholm is proposed as new Chair of the Sobi Board of Directors
The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi®) proposes that Börje Ekholm is elected as new Board member and Chair of the Board at the 2027 Annual General Meeting (AGM). STOCKHOLM, Oc...
Swedish Orphan price target raised to SEK 600 from SEK 575 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 600 from SEK 575 and keeps a Buy rating on the shares following the Q3 report.
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto
Pareto analyst Filip Wiberg upgraded Swedish Orphan Biovitrum (BIOVF) to Buy from Hold with a SEK 530 price target
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q3 2026
Q3 revenue grew 16% CER and 26% excluding Beyfortus royalties, lifting FY26 revenue guidance. Strong product and regional growth was balanced by higher launch and R&D investment and uncertainty around RSV royalties.
Swedish Orphan Biovitrum AB Quarterly report: Q3 2026
Swedish Orphan Biovitrum AB has published its Q3 2026 quarterly earnings report on October 27, 2026.
Swedish Orphan Biovitrum AB Slides: Q3 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Swedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of +14.52% and +4.09%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for th...
Sobi Q3 2026 report: Underpinning a strong growth momentum
STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026 Total revenue increased 16 per cent at CER ...
Swedish Orphan Biovitrum downgraded to Hold from Buy at Nordea
Nordea downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy.
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline
Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Swedish Orphan Biovitrum AB Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong financial growth and upgraded guidance were driven by successful product launches and pipeline progress. Key franchises like ALTUVOCT, ASPAVELI, and Gamifant are expanding, while new opportunities in gout and lipidology are being pursued. Strategic partnerships and organizational transformation support long-term ambitions.
Swedish Orphan Biovitrum AB Slides: SEB Nordic Large Cap Seminar presentation
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Swedish Orphan Biovitrum price target raised to SEK 515 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 515 from SEK 490 and keeps a Buy rating on the shares.
Swedish Orphan Biovitrum price target raised to SEK 575 at Berenberg
Berenberg raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 575 from SEK 550 and keeps a Buy rating on the shares.
Biovitrum price target raised to SEK 575 from SEK 550 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 575 from SEK 550 and keeps a Buy rating on the shares. The firm says the…
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Carnegie
DNB Carnegie downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 475 price target
Swedish Orphan Biovitrum AB Slides: Investor presentation
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2026.
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q2 2026
Q2 saw 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products like ALTUVOCT, Doptelet, and Gamifant. The outlook for 2026 was raised, with continued pipeline progress and new launches supporting long-term growth.
Swedish Orphan Biovitrum AB Quarterly report: Q2 2026
Swedish Orphan Biovitrum AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Swedish Orphan Biovitrum AB Slides: Q2 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Swedish Orphan price target raised to SEK 530 from SEK 470 at Barclays
Barclays raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 530 from SEK 470 and keeps an Overweight rating on the shares.
Swedish Orphan Biovitrum downgraded to Hold from Buy at Pareto
Pareto downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 470 price target The firm cites valuation following the stock’s recent rally for the downgrade. Published first…
Swedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Swedish Orphan Biovitrum (BIOVF) with a Buy rating and SEK 530 price target Sobi is a profitable, cash-generative rare-disease biopharma c...
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% revenue growth and a 38% adjusted EBITDA margin, driven by strong launches and portfolio expansion. Key products like ALTUVOCT, Gamifant, Aspaveli, and Doptelet delivered robust growth, and the outlook for 2026 remains positive with continued investment in launches and R&D.
Swedish Orphan Biovitrum AB Quarterly report: Q1 2026
Swedish Orphan Biovitrum AB has published its Q1 2026 quarterly earnings report on April 28, 2026.